mCapOX plus cetuximab

Phase 3Monoclonal antibody

WWest China Hospital

mCapOX plus cetuximab is one of 65 small molecule programs targeting Metastatic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastaticRecruiting

First-Line TreatmentNot yet recruiting

MetastaticPhase 2

Recruiting

First-Line TreatmentPhase 3

Not yet recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 6

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 7

Effexor

WWyeth-Lederle Vaccines

Phase 3

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 9

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 10

Lithobid

SSolvay Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

First-Line Treatment

NCT06616259

Clinical

Trials by Indication[1]

First-line Treatment1 trial

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Not yet recruiting·MMeng Qiu·Phase 3·NCT06616259·452 enrolled

Metastatic1 trial

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Recruiting·WWest China Hospital·Phase 2·NCT05022030·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mCapOX plus cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mCapOX plus cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mCapOX plus cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: WWest China Hospital

mCapOX plus cetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

First-line Treatment1 trial

Metastatic1 trial

References

Drug Info

Quick Facts

Related News